Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis

Serena Camassa1, Ivana Palucci1, Raffaella Iantomasi2

  • 1Institute of Microbiology, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario GemelliRome, Italy.

Insights

Polymorphisms in the PE_PGRS33 gene of Mycobacterium tuberculosis (Mtb) impact its function in macrophages and virulence. Mutations impair Mtb entry but enhance tissue damage, suggesting PE_PGRS33

Area of Science:

  • Microbiology
  • Genetics
  • Immunology

Background:

  • PE_PGRS33 is a surface protein of Mycobacterium tuberculosis (Mtb) involved in macrophage entry and immunomodulation.
  • Understanding genetic variations in PE_PGRS33 is crucial for elucidating Mtb pathogenesis.

Purpose of the Study:

  • To investigate polymorphisms in the pe_pgrs33 gene of Mtb clinical isolates.
  • To evaluate the functional impact of these polymorphisms on Mtb virulence and host-pathogen interactions.

Main Methods:

  • Sequencing of the pe_pgrs33 gene in 135 Mtb clinical strains.
  • Genotyping using 15-loci MIRU-VNTR and spoligotyping.
  • Functional analysis of complemented Mtb knockout mutants in vitro (macrophage infection) and in vivo (murine TB model).

Main Results:

  • An association was observed between pe_pgrs33 alleles and Mtb complex (MTBC) genotypes, with evidence of purifying selection on the gene.
  • Large mutations in pe_pgrs33 impaired Mtb entry into macrophages but not intracellular replication or immunomodulation.
  • Mtb lacking PE_PGRS33 (MtbΔ33) showed enhanced virulence and caused greater lung tissue damage during chronic infection in mice.

Conclusions:

  • PE_PGRS33 plays a significant role in Mtb pathogenesis and virulence.
  • Specific polymorphisms in pe_pgrs33 can modulate Mtb's interaction with the host, leading to increased tissue damage.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
80
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53